Clinical trial NCT06841536: Combined Effects of Statins and Exercise on Training Sensitive Health Markers
Official title: Combined Effects of Statins and Exercise on Physiological Health Markers and Quality of Life in Patients With Dyslipidaemia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Dyslipidemias
Keywords: Dyslipidemia
Exercise training
Mitochondria
Aerobic capacity
Statins
Adaptation, Physiological
proteomics
genetics
quality of life
Lead sponsor: University of the Faroe Islands
Sponsor class: OTHER
Collaborators: name: University of Copenhagen
name: Research council Faroe Islands
name: National Hospital of the Faroe Islands
name: Betri Stuðul
First posted: 2025-02-24
Enrollment: 100
Sex: ALL
Minimum age (years): 40
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants will be randomized by block to achieve a 60 : 40 allocation between exercise and non-exercise conditions, stratified by (1) sex (male/female) and (2) prior statin use (yes/no). The four 12-week treatment arms are: 1) exercise + placebo, 2) exercise + atorvastatin (80 mg/day), 3) atorvastatin (80 mg/day) and 4) placebo for 12 weeks
Primary purpose: BASIC_SCIENCE

Brief summary: Around the world, about 4 in 10 adults have abnormal blood fat levels-known as dyslipidaemia-which raises their chances of getting heart disease. Many people with this condition are prescribed statins, medications that help lower the "bad" Low-density lipoprotein cholesterol (LDL-C) in the blood and, in doing so, help prevent serious heart-related problems. While statins do lower these harmful cholesterol levels, recent research suggests that statins might interfere with some of the positive effects that exercise typically has on muscle cells' energy centers (the mitochondria) and on a person's aerobic capacity. It is not yet fully understood how statins might influence these exercise benefits at the molecular level. To address this gap, the present study will look closely at how taking statins combined with a structured exercise program affects both the muscle cells and the whole-body fitness of people with dyslipidaemia. By using a wide-ranging protein analysis, the research aims to identify changes in muscle proteins and other metabolism-related factors that could explain why statins might alter the expected improvements from exercise.

Methods and Analysis In this 12-week study, 100 adults between the ages of 40 and 65 who have dyslipidaemia but no established heart disease will take part. Participants will be randomly split into one of four groups: (1) exercise plus a placebo (an inactive pill), (2) exercise plus a daily high-dose statin (atorvastatin, 80 mg), (3) a daily high-dose statin without exercise, or (4) a placebo without exercise. More participants will be placed in the exercise groups to better understand the combined effects of exercise and statins. The main measurement will be how well the muscle's mitochondria work, assessed by changes in an enzyme called citrate synthase (CS) from before the program to after. Other important measures will include overall fitness (using a peak oxygen uptake (VO2peak) test) and detailed protein analyses. The study will also look at genetic variations to see if they influence how each participant responds to the treatment.

Ethics and Sharing of Results The study has received approval from the Faroe Islands Ethical Committee (2024-10) and follows international guidelines to protect participants' rights and data. Once the research is complete, the findings will be shared in leading scientific journals for the broader public and medical community to learn from.

Detailed description: Dyslipidaemia, defined by abnormal lipid profiles (including raised total cholesterol, LDL-C, and triglycerides, as well as reduced high-density lipoprotein cholesterol (HDL-C), affects close to 40% of adults aged 25 years and above worldwide. This condition significantly contributes to global morbidity and mortality. In particular, excess LDL-C has been associated with elevated atherosclerotic cardiovascular disease (ASCVD) risk due to its central role in cholesterol transport into the arterial wall, facilitating plaque formation and atherogenesis. The scale of the problem is illustrated by data indicating that high LDL-C levels were linked to approximately 4.40 million deaths and 98.62 million Disability-adjusted life years in 2019 alone. Notably, the highest regional prevalence of hypercholesterolaemia has been reported in Europe, where more than half of the adult population exhibits elevated plasma cholesterol concentrations. The reduction of circulating LDL-C, whether through pharmacological agents or lifestyle interventions, thus remains a key strategy in mitigating ASCVD risk.

Among available therapies, statins are a cornerstone of dyslipidaemia management due to their efficacy in lowering LDL-C and consequent reduction in cardiovascular event rates. For instance, decreasing LDL-C by 1 mmol/L through statin therapy is associated with up to a 20% reduction in both cardiovascular events and all-cause mortality. While pharmacotherapy is central to risk management, exercise training is also strongly recommended to improve lipid profiles and enhance cardiovascular health. Even relatively modest increases in cardiorespiratory fitness (CRF), on the order of approximately 1 metabolic equivalent (MET), translate into significant survival benefits of 10-25%. As cardiovascular diseases remain a leading global health concern, understanding how statins may interact with exercise-based interventions is essential for developing optimized treatment strategies for patients with dyslipidaemia.

Recent evidence suggests that the concurrent use of statins and structured exercise training does not always produce additive benefits, as initially presumed. In particular, some studies have reported that statin therapy may attenuate improvements in CRF and skeletal muscle mitochondrial function typically observed with endurance training. For example, administration of simvastatin at 40 mg/day hindered the usual exercise-induced increase in citrate synthase (CS) activity and aerobic capacity following 12 weeks of endurance exercise training in overweight adults. Similarly, high-dose atorvastatin (80 mg/day) has been shown to impair mitochondrial oxidative capacity in skeletal muscle, even in individuals free from overt cardiometabolic disease. These results are consistent with a growing body of work linking statin use to mitochondrial perturbations within skeletal muscle tissue. However, the precise biological mechanisms responsible for these observations remain poorly characterized. Modern omics approaches, such as untargeted proteomic profiling, may help elucidate how statins impact the network of mitochondrial proteins and metabolic pathways involved in exercise adaptation.

In addition to mitochondrial dysregulation, statin therapy-particularly at high doses-has been associated with a heightened risk of incident type 2 diabetes mellitus (T2DM). The underlying mechanisms appear multifactorial, involving alterations in insulin sensitivity and secretory function. Statins may diminish Glucose transporter type 4 (GLUT4)-mediated glucose uptake, affect mitochondrial energy transduction in skeletal muscle and adipose tissue, and promote lipotoxicity in pancreatic beta cells, collectively increasing insulin resistance and impairing normal insulin secretion. Thus, while statins robustly lower LDL-C and cardiovascular risk, their influence on glycemic control and metabolic health parameters warrants careful patient selection and ongoing glucose monitoring, especially in individuals predisposed to diabetes.

Musculoskeletal side effects, referred to as statin-associated muscle symptoms (SAMS), are another important consideration. Affecting an estimated 5-30% of statin users, SAMS range from mild myalgias to more significant muscle weakness, potentially prompting discontinuation of therapy and reducing adherence. This issue may also discourage regular physical activity and thereby negate some of the positive lifestyle modifications critical for long-term health management. Physical exertion may exacerbate these muscle symptoms, promoting a more sedentary pattern in individuals on statins. Although the pathophysiology of SAMS is not fully delineated, mitochondrial dysfunction related to impaired complexes III and IV activity, as well as reduced coenzyme Q10 availability, has been implicated.

Moreover, genetic polymorphisms can modulate statin pharmacodynamics and pharmacokinetics, potentially altering muscle tissue statin exposure and influencing inter-individual variability in both therapeutic and adverse responses to these agents. To date, however, the extent to which genetic variation might modify the interaction between statin therapy and exercise adaptations (on parameters such as mitochondrial function and systemic fitness) remains unknown.

In summary, although statins effectively diminish ASCVD risk by lowering LDL-C, emerging data suggest statins can reduce the beneficial effects of exercise training on skeletal muscle mitochondria and CRF. In addition, high-dose statin therapy may increase susceptibility to T2DM and aggravate muscle-related symptoms, thereby influencing the overall therapeutic benefit-risk profile. Despite considerable investigation in related areas, the precise molecular mechanisms underlying these effects, as well as the influence of genetics on this interplay, remain unclear. Notably, previous research has not yet encompassed a comprehensive, randomized, double-blinded, placebo-controlled trial that examines the simultaneous impact of statin therapy and structured exercise training on cardiovascular, muscular, and metabolic endpoints in dyslipidaemic individuals aged 40-65 years, including in-depth molecular phenotyping and genetic analyses.

Objective The present study aims to determine how statin therapy and exercise training, alone and in combination, influence whole-body aerobic capacity and mitochondrial function in individuals with dyslipidaemia but without established ASCVD. By employing untargeted proteomic methods, the investigation will identify molecular signatures and pathways through which statins may modify exercise-induced alterations in mitochondrial protein composition and metabolic phenotypes. An embedded sub-analysis will evaluate the role of genetic polymorphisms influencing statin pharmacodynamics and pharmacokinetics, thereby assessing how these genetic factors might shape individual variability in responses at both the muscle tissue and systemic levels. This integrative approach is expected to advance our understanding of the complex interactions between pharmacological lipid-lowering strategies and lifestyle interventions, ultimately guiding personalized management plans for patients with dyslipidaemia.

Eligibility criteria: Inclusion Criteria:

* Age: 40-65 years
* LDL-C \> 4.0 mmol/L.

Exclusion Criteria:

* Diagnosed with serious chronic disease including type 1 or 2 diabetes.
* Cancer.
* A history of atherosclerotic cardiovascular disease.
* A history of major depression or other severe psychiatric disorders.
* Severe renal dysfunction (creatinine clearance \<30 mL/min).
* Severe hepatic impairment.
* Active pregnancy or breast feeding.
* Active cigarette or e-cigarette smoker.
* Regular (\>2 hours pr week) aerobic high-intensity exercise training.

Primary outcomes:
measure: Citrate synthase maximal activity (µmol/g/min)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
Secondary outcomes:
measure: Maximal oxygen uptake (ml/min)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Targeted skeletal muscle proteomics
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Lipid profile (mmol/L)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Concentration of lipoprotein (a) (nmol/L)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Concentration of apolipoprotein B (nmol/L)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Statins (atorvastatin) accumulation in muscle tissue
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Skeletal muscle coenzyme Q10
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Body weight (kg)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Fasting plasma glucose (mmol/L)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Concentration of glycosylated hemoglobin A1c (HbA1c) (mmol/mol)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Blood pressure (mmHg)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Resting heart rate (bpm)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Steady-state systemic oxygen uptake (mL/min)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Quality of life score
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Maximal 3-hydroxy-acetylCoa-dehydrogenase activity (µmol/g/min).
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Maximal phosphofructokinase activity (µmol/g/min)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Waist and hip circumference (cm)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Body fat percentage (%)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Body fat mass (kg)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Lean body mass (kg)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Hand-grip strength (kg)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Mitochondrial expression of complex I (arbitrary units)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: HOMA-IR
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Matsuda Index
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Insulin secretion rate (ISR)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Oral disposition index
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Statin-associated muscle symptoms (SAMS)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Statin-associated muscle symptoms (SAMS)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Statin-associated muscle symptoms (SAMS)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Statin-associated muscle symptoms (SAMS)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Mitochondrial expression of complex II (arbitrary units)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Mitochondrial expression of complex III (arbitrary units)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Mitochondrial expression of complex IV (arbitrary units)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Mitochondrial expression of complex V (arbitrary units)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
Other outcomes:
measure: Anaerobic capacity
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Concentration of systemic coenzyme Q10
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Total hemoglobin mass (g)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Concentration of systemic markers of inflammation (fg/mL)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Concentration of C-reactive protein (mg/L)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Concentration of white blood cells (10^9/L)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Telomere length
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Concentration of per- and polyfluoroalkyl substances (PFAS)
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Rate of perceived exertion (RPE) during exercise sessions
timeFrame: Measured frequently throughout the intervention
measure: Rate of perceived exertion (RPE) during exercise capacity measurements
timeFrame: Change from baseline to end-of-treatment (12 weeks)
measure: Untargeted skeletal muscle proteomics
timeFrame: Change from baseline to end-of-treatment (12 weeks)
Locations:
city: Tórshavn
country: Faroe Islands
facility: University of the Faroe Islands
Study officials:
References:
citation: Kopin L, Lowenstein C. Dyslipidemia. Ann Intern Med. 2017 Dec 5;167(11):ITC81-ITC96. doi: 10.7326/AITC201712050.
citation: Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, Nordestgaard BG, Watts GF, Bruckert E, Fazio S, Ference BA, Graham I, Horton JD, Landmesser U, Laufs U, Masana L, Pasterkamp G, Raal FJ, Ray KK, Schunkert H, Taskinen MR, van de Sluis B, Wiklund O, Tokgozoglu L, Catapano AL, Ginsberg HN. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020 Jun 21;41(24):2313-2330. doi: 10.1093/eurheartj/ehz962. No abstract available.
citation: Kokkinos PF, Faselis C, Myers J, Panagiotakos D, Doumas M. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet. 2013 Feb 2;381(9864):394-9. doi: 10.1016/S0140-6736(12)61426-3. Epub 2012 Nov 28.
citation: Farrell SW, Finley CE, Grundy SM. Cardiorespiratory fitness, LDL cholesterol, and CHD mortality in men. Med Sci Sports Exerc. 2012 Nov;44(11):2132-7. doi: 10.1249/MSS.0b013e31826524be.
citation: Mikus CR, Boyle LJ, Borengasser SJ, Oberlin DJ, Naples SP, Fletcher J, Meers GM, Ruebel M, Laughlin MH, Dellsperger KC, Fadel PJ, Thyfault JP. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol. 2013 Aug 20;62(8):709-14. doi: 10.1016/j.jacc.2013.02.074. Epub 2013 Apr 10.
citation: Morales-Palomo F, Ramirez-Jimenez M, Ortega JF, Moreno-Cabanas A, Mora-Rodriguez R. Exercise Training Adaptations in Metabolic Syndrome Individuals on Chronic Statin Treatment. J Clin Endocrinol Metab. 2020 Apr 1;105(4):dgz304. doi: 10.1210/clinem/dgz304.
citation: Ryan TE, Torres MJ, Lin CT, Clark AH, Brophy PM, Smith CA, Smith CD, Morris EM, Thyfault JP, Neufer PD. High-dose atorvastatin therapy progressively decreases skeletal muscle mitochondrial respiratory capacity in humans. JCI Insight. 2024 Feb 22;9(4):e174125. doi: 10.1172/jci.insight.174125.
citation: Allard NAE, Schirris TJJ, Verheggen RJ, Russel FGM, Rodenburg RJ, Smeitink JAM, Thompson PD, Hopman MTE, Timmers S. Statins Affect Skeletal Muscle Performance: Evidence for Disturbances in Energy Metabolism. J Clin Endocrinol Metab. 2018 Jan 1;103(1):75-84. doi: 10.1210/jc.2017-01561.
citation: Paiva H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, Laakso J, Lehtimaki T, von Bergmann K, Lutjohann D, Laaksonen R. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther. 2005 Jul;78(1):60-8. doi: 10.1016/j.clpt.2005.03.006.
citation: Schirris TJ, Renkema GH, Ritschel T, Voermans NC, Bilos A, van Engelen BG, Brandt U, Koopman WJ, Beyrath JD, Rodenburg RJ, Willems PH, Smeitink JA, Russel FG. Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition. Cell Metab. 2015 Sep 1;22(3):399-407. doi: 10.1016/j.cmet.2015.08.002.
citation: Sirvent P, Bordenave S, Vermaelen M, Roels B, Vassort G, Mercier J, Raynaud E, Lacampagne A. Simvastatin induces impairment in skeletal muscle while heart is protected. Biochem Biophys Res Commun. 2005 Dec 23;338(3):1426-34. doi: 10.1016/j.bbrc.2005.10.108. Epub 2005 Oct 26.
citation: Sirvent P, Mercier J, Vassort G, Lacampagne A. Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. Biochem Biophys Res Commun. 2005 Apr 15;329(3):1067-75. doi: 10.1016/j.bbrc.2005.02.070.
citation: Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol. 2006 Dec;291(6):C1208-12. doi: 10.1152/ajpcell.00226.2006. Epub 2006 Aug 2.
citation: Muraki A, Miyashita K, Mitsuishi M, Tamaki M, Tanaka K, Itoh H. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance. J Appl Physiol (1985). 2012 Aug;113(3):479-86. doi: 10.1152/japplphysiol.01362.2011. Epub 2012 May 31.
citation: Bouitbir J, Charles AL, Rasseneur L, Dufour S, Piquard F, Geny B, Zoll J. Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress. J Appl Physiol (1985). 2011 Nov;111(5):1477-83. doi: 10.1152/japplphysiol.00107.2011. Epub 2011 Aug 18.
citation: Kwak HB, Thalacker-Mercer A, Anderson EJ, Lin CT, Kane DA, Lee NS, Cortright RN, Bamman MM, Neufer PD. Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic Biol Med. 2012 Jan 1;52(1):198-207. doi: 10.1016/j.freeradbiomed.2011.10.449. Epub 2011 Oct 25.
citation: Sirvent P, Fabre O, Bordenave S, Hillaire-Buys D, Raynaud De Mauverger E, Lacampagne A, Mercier J. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol. 2012 Mar 1;259(2):263-8. doi: 10.1016/j.taap.2012.01.008. Epub 2012 Jan 17.
citation: Schick BA, Laaksonen R, Frohlich JJ, Paiva H, Lehtimaki T, Humphries KH, Cote HC. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther. 2007 May;81(5):650-3. doi: 10.1038/sj.clpt.6100124. Epub 2007 Feb 28.
citation: Meador BM, Huey KA. Statin-associated changes in skeletal muscle function and stress response after novel or accustomed exercise. Muscle Nerve. 2011 Dec;44(6):882-9. doi: 10.1002/mus.22236.